SOURCE: Radient Pharmaceuticals Corporation

December 02, 2009 19:38 ET

Radient Pharmaceutical Corporation's CEO & Chairman Mr. Douglas MacLellan Featured on "The Money Channel's American Scene Radio"

TUSTIN, CA--(Marketwire - December 2, 2009) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC), announced today its Chairman and CEO Mr. Douglas MacLellan will be featured on "The Money Channel's American Scene Radio" with host Steve Crowley to discuss Radient Pharmaceutical's 2010 growth strategy and the Company's worldwide commercialization plan for its Onko-Sure™ In Vitro (IVD) cancer test and Elleuxe™ high-end skin care product line.

According to Steve Crowley of "The Money Channel's American Scene Radio," "I have followed this Company's progress closely for five years and see Radient Pharmaceuticals as a strong growth and value play. We ask our listeners and viewers to complete their due diligence on the Company right now because management has forecasted profitability early in 2010 and we believe the stock is extremely undervalued based upon its potential revenues, very high margins, and portfolio of intellectual properties."

Douglas MacLellan, Chairman and CEO comments, "We believe we have established a low risk path to profitability in fiscal year 2010 and are very confident in Radient Pharmaceutical's future prospects -- specifically with the launch and commercialization of our Onko-Sure IVD cancer test and Elleuxe skin care line, and the monetization of our China-based subsidiary Jade Pharmaceuticals, Inc. We believe the Company offers a compelling investment opportunity and we encourage prospective investors to engage in the business."

Radient Pharmaceuticals is focused on the research, development, manufacturing, sales and marketing of in vitro diagnostics and high-end skin care products, including its Onko-Sure IVD cancer test and Elleuxe skin care product line. The Company has secured regulatory approval in the US and several other international markets for Onko-Sure and began commercializing the product in the second quarter of fiscal year 2009. Radient Pharmaceutical's goal is to establish Onko-Sure as the premiere test for general cancer screening and monitoring in strategic markets within the next five years and is projecting $17.2 million in product gross revenues in 2010, $50.7 million in year 2012, and $107.9 million by 2014. In 2010 the Company will also officially launch the Elleuxe skin care product line.

The Money Channel brings Radient Pharmaceuticals daily exposure to the investing public. Programming includes weekday Investor Showcase Radio segments, including interviews on the American Scene Radio program from this week through May 1, 2010. Radient Pharmaceuticals will also present at the World Money Show in early February 2010 (Orlando, FL) in the Money Channel's Broadcast Booth in order to meet and greet potential new investors and money managers. The Money Channel will produce a televised feature segment there, to be aired on its "WallStreetCast" program which airs weekends on the Fox Business Network (FBN) nationwide.

Doug MacLellan's interview is scheduled for Thursday, December 3, 2009 at 9:00 AM Pacific Standard Time and will be available as an audio download through The Money Channel website located at For additional information on Radient Pharmaceuticals and its portfolio of products, visit the Company's corporate website at For Investor Relations information, contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323